Sonnet BioTherapeutics Up 66% in Regular Session on Collaboration With Janssen
October 31 2022 - 7:13PM
Dow Jones News
By Josh Beckerman
Shares of Sonnet BioTherapeutics Holdings Inc. surged 66% to
$1.93 in Monday's regular session after the company announced a
collaboration agreement with Janssen Biotech Inc. The stock rose
10% to $2.13 after hours.
Janssen is part of Johnson & Johnson.
SON-1010, SON-1210 and SON-1410 will be evaluated in combination
with certain Janssen proprietary cell therapy assets.
"This is Sonnet's first head-to-head evaluation of three
FHAB-based drug candidates, the results of which will be
instructive for expanded oncology indications," the company
said.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 31, 2022 18:58 ET (22:58 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jul 2023 to Jul 2024